New trial will test the safety of dapivirine ring and usage of daily oral antiviral tablet for HIV pre-exposure prophylaxis (PrEP) in pregnant women . It also assesses how much they accept and use these two HIV prevention tools.
The study will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first six months after birth. PrEP is available in some countries and is being rolled out in others, while the dapivirine ring is under regulatory review by the European Medicines Agency for potential use in sub-Saharan Africa.
